Join our daily newsletter At The Bell to receive exclusive market insights
- The CD Private Equity Fund Series, which consists of three ASX-listed funds and one private fund, has released its latest half-year updates
- Fund III (CD3) reported the best increase in investment income, jumping up 892 per cent to $44.2 million, with an operating profit of $40.6 million
- Fund II (CD2) recorded a 340.3 per cent jump in investment income to $25.6 million, while Fund I (CD1) hit $11.9 million in investment income, up 246.6 per cent
- All of the funds offer investments in small-to-mid sized private investment funds and companies which are based in North America
- Shares in CD1 opened Tuesday at $1.38, while CD2 was trading at $1.66 and CD3 for $1.85
The CD Private Equity Fund Series has released its latest half-year update for all three of its ASX-listed funds.
The series consists of the three listed funds as well as a fourth unlisted fund with each offering investments in small-to-mid sized US private investment funds and companies.
Fund III (CD3) reported the best increase in investment income over the six month period, jumping up 892 per cent to $44.2 million, with an operating profit of $40.6 million.
This fund is the newest of CD’s listed funds and gave investors total returns of 27.5 per cent on a post-tax net asset value basis over the six months to September 30.
Fund II (CD2) recorded a 340.3 per cent jump in investment income to $25.6 million and a net operating profit of $21.4 million and total returns of 21.3 per cent.
Finally, Fund I (CD1) hit $11.9 million in investment income, up 246.6 per cent, and recorded an operating profit of $10.8 million.
CD1 has eight underlying fund managers and is the older of the CD Private Equity funds, offering returns of 23.1 per cent on a post-tax net asset value basis.
All of CD Private Equity’s listed funds are backed by the Cordish families, who own the US-based real estate and entertainment business, Cordish Companies.
Shares in CD1 opened Tuesday at $1.38, while CD2 was trading at $1.66 and CD3 for $1.85 at the open of market on November 30.
